Jose Meade
@josemeade.bsky.social
IM PGY-3 Boston University - Interests include but not limited to PCCM, #POCUS, meded and autoimmunity #RheumCrit 🩺⚕️
Thank you for all your mentorship and support throughout!!! You are an amazing mentor and person!
December 3, 2025 at 7:25 PM
Thank you for all your mentorship and support throughout!!! You are an amazing mentor and person!
Reposted by Jose Meade
My research mentee matched to Mayo Clinic Pulm Crit!!
Sooo happy for @josemeade.bsky.social, congrats!!
#Fellowship #Match #MatchDay
Sooo happy for @josemeade.bsky.social, congrats!!
#Fellowship #Match #MatchDay
December 3, 2025 at 5:33 PM
My research mentee matched to Mayo Clinic Pulm Crit!!
Sooo happy for @josemeade.bsky.social, congrats!!
#Fellowship #Match #MatchDay
Sooo happy for @josemeade.bsky.social, congrats!!
#Fellowship #Match #MatchDay
Reposted by Jose Meade
📣 Calling all MD & DO students (including MD/PhD, DO/PhD, MD/MPH, DO/MPH)!
Apply for the Rheumatology Future Physician Scientist Award, supporting research training for future physician-scientists in rheumatology.
🗓️ Applications due Dec 1, 2025 by 5 PM ET rheumresearch.org/preceptorships#RFPS
Apply for the Rheumatology Future Physician Scientist Award, supporting research training for future physician-scientists in rheumatology.
🗓️ Applications due Dec 1, 2025 by 5 PM ET rheumresearch.org/preceptorships#RFPS
November 7, 2025 at 3:01 PM
📣 Calling all MD & DO students (including MD/PhD, DO/PhD, MD/MPH, DO/MPH)!
Apply for the Rheumatology Future Physician Scientist Award, supporting research training for future physician-scientists in rheumatology.
🗓️ Applications due Dec 1, 2025 by 5 PM ET rheumresearch.org/preceptorships#RFPS
Apply for the Rheumatology Future Physician Scientist Award, supporting research training for future physician-scientists in rheumatology.
🗓️ Applications due Dec 1, 2025 by 5 PM ET rheumresearch.org/preceptorships#RFPS
Reposted by Jose Meade
October 27, 2025 at 5:41 PM
Reposted by Jose Meade
Dr. Martha Delgado gave a great #ACR25 presentation focused on improving patient participation in clinical trials in Latino communities. She shared barriers for both patients & providers as well current efforts to remove barriers.
cc: @ladaorg.bsky.social #LADAorg @lupuschat.bsky.social #LupusChat
cc: @ladaorg.bsky.social #LADAorg @lupuschat.bsky.social #LupusChat
October 27, 2025 at 6:42 PM
Dr. Martha Delgado gave a great #ACR25 presentation focused on improving patient participation in clinical trials in Latino communities. She shared barriers for both patients & providers as well current efforts to remove barriers.
cc: @ladaorg.bsky.social #LADAorg @lupuschat.bsky.social #LupusChat
cc: @ladaorg.bsky.social #LADAorg @lupuschat.bsky.social #LupusChat
Reposted by Jose Meade
We wrote an article explaining why you shouldn't put several variables into a regression model and report which are statistically significant - even as exploratory research. bmjmedicine.bmj.com/content/4/1/.... How did we do?
October 27, 2025 at 5:39 PM
We wrote an article explaining why you shouldn't put several variables into a regression model and report which are statistically significant - even as exploratory research. bmjmedicine.bmj.com/content/4/1/.... How did we do?
Today, in collaboration with @BUMedicine Emergency Medicine, we shared some basic POCUS skills to our second-year medical students. Let’s keep integrating POCUS into medical school curricula!
October 22, 2025 at 11:04 PM
Today, in collaboration with @BUMedicine Emergency Medicine, we shared some basic POCUS skills to our second-year medical students. Let’s keep integrating POCUS into medical school curricula!
Reposted by Jose Meade
This October I’m drawing 1 molecule a day inspired by proteins in pdb @rcsbpdb.bsky.social
Day 13
Prompt DRINK
Pdb: 7BTW
A pair of mitochondrial outer membrane β-barrel SAM complexes from Saccharomyces cerevisiae, the yeast used to make beer.
Cheers!
Next: TRUNK
Suggestions?
Day 13
Prompt DRINK
Pdb: 7BTW
A pair of mitochondrial outer membrane β-barrel SAM complexes from Saccharomyces cerevisiae, the yeast used to make beer.
Cheers!
Next: TRUNK
Suggestions?
October 14, 2025 at 5:57 AM
This October I’m drawing 1 molecule a day inspired by proteins in pdb @rcsbpdb.bsky.social
Day 13
Prompt DRINK
Pdb: 7BTW
A pair of mitochondrial outer membrane β-barrel SAM complexes from Saccharomyces cerevisiae, the yeast used to make beer.
Cheers!
Next: TRUNK
Suggestions?
Day 13
Prompt DRINK
Pdb: 7BTW
A pair of mitochondrial outer membrane β-barrel SAM complexes from Saccharomyces cerevisiae, the yeast used to make beer.
Cheers!
Next: TRUNK
Suggestions?
6️⃣ The big picture
Early TNFi ≠ less opioid use.
Future work should include pain scores, disease activity, and social factors to fully understand pain and opioid trajectories in axSpA.
#Rheumatology #axSpA #Opioids #TNFi #Pharmacoepidemiology
Early TNFi ≠ less opioid use.
Future work should include pain scores, disease activity, and social factors to fully understand pain and opioid trajectories in axSpA.
#Rheumatology #axSpA #Opioids #TNFi #Pharmacoepidemiology
The Effect of Early Tumor Necrosis Factor Inhibitor Initiation on Chronic Opioid Use in Individuals with Axial Spondylarthritis
Objective Opioid use remains common despite effective therapies for axial spondyloarthritis (axSpA). We assessed whether early tumor necrosis factor inhibitor (TNFi) use is associated with reduced r...
acrjournals.onlinelibrary.wiley.com
October 14, 2025 at 3:15 PM
6️⃣ The big picture
Early TNFi ≠ less opioid use.
Future work should include pain scores, disease activity, and social factors to fully understand pain and opioid trajectories in axSpA.
#Rheumatology #axSpA #Opioids #TNFi #Pharmacoepidemiology
Early TNFi ≠ less opioid use.
Future work should include pain scores, disease activity, and social factors to fully understand pain and opioid trajectories in axSpA.
#Rheumatology #axSpA #Opioids #TNFi #Pharmacoepidemiology
5️⃣ Why it matters
💡 Chronic opioid use is still common (~21%) in axSpA
💥 Biologic therapy alone may not solve the opioid problem
🧠 Need multimodal, holistic pain strategies
💡 Chronic opioid use is still common (~21%) in axSpA
💥 Biologic therapy alone may not solve the opioid problem
🧠 Need multimodal, holistic pain strategies
October 14, 2025 at 3:15 PM
5️⃣ Why it matters
💡 Chronic opioid use is still common (~21%) in axSpA
💥 Biologic therapy alone may not solve the opioid problem
🧠 Need multimodal, holistic pain strategies
💡 Chronic opioid use is still common (~21%) in axSpA
💥 Biologic therapy alone may not solve the opioid problem
🧠 Need multimodal, holistic pain strategies
4️⃣ Takeaway
❌ Early TNFi use did not reduce opioid use.
📈 In opioid-naïve patients, it was linked to higher chronic use.
Likely due to confounding by indication — patients with worse disease start TNFi earlier and need more pain control.
❌ Early TNFi use did not reduce opioid use.
📈 In opioid-naïve patients, it was linked to higher chronic use.
Likely due to confounding by indication — patients with worse disease start TNFi earlier and need more pain control.
October 14, 2025 at 3:15 PM
4️⃣ Takeaway
❌ Early TNFi use did not reduce opioid use.
📈 In opioid-naïve patients, it was linked to higher chronic use.
Likely due to confounding by indication — patients with worse disease start TNFi earlier and need more pain control.
❌ Early TNFi use did not reduce opioid use.
📈 In opioid-naïve patients, it was linked to higher chronic use.
Likely due to confounding by indication — patients with worse disease start TNFi earlier and need more pain control.
3️⃣ Results
8,508 matched individuals (mean age 42, 50% women).
💊 Chronic opioid use in 20.9% overall.
⚠️ Early TNFi = higher risk (HR 1.17, 95% CI 1.06–1.28).
Opioid-naïve: HR 1.96 🚨
Opioid-experienced: NS
8,508 matched individuals (mean age 42, 50% women).
💊 Chronic opioid use in 20.9% overall.
⚠️ Early TNFi = higher risk (HR 1.17, 95% CI 1.06–1.28).
Opioid-naïve: HR 1.96 🚨
Opioid-experienced: NS
October 14, 2025 at 3:15 PM
3️⃣ Results
8,508 matched individuals (mean age 42, 50% women).
💊 Chronic opioid use in 20.9% overall.
⚠️ Early TNFi = higher risk (HR 1.17, 95% CI 1.06–1.28).
Opioid-naïve: HR 1.96 🚨
Opioid-experienced: NS
8,508 matched individuals (mean age 42, 50% women).
💊 Chronic opioid use in 20.9% overall.
⚠️ Early TNFi = higher risk (HR 1.17, 95% CI 1.06–1.28).
Opioid-naïve: HR 1.96 🚨
Opioid-experienced: NS
2️⃣ Methods
🧾 MarketScan® claims data (US)
👥 Adults 18–65 with new axSpA
⚕️ “Early TNFi” = started ≤6 months after diagnosis
📊 Propensity score–matched 1:1
💊 Outcome: chronic opioid use ≥90 days
🧾 MarketScan® claims data (US)
👥 Adults 18–65 with new axSpA
⚕️ “Early TNFi” = started ≤6 months after diagnosis
📊 Propensity score–matched 1:1
💊 Outcome: chronic opioid use ≥90 days
October 14, 2025 at 3:15 PM
2️⃣ Methods
🧾 MarketScan® claims data (US)
👥 Adults 18–65 with new axSpA
⚕️ “Early TNFi” = started ≤6 months after diagnosis
📊 Propensity score–matched 1:1
💊 Outcome: chronic opioid use ≥90 days
🧾 MarketScan® claims data (US)
👥 Adults 18–65 with new axSpA
⚕️ “Early TNFi” = started ≤6 months after diagnosis
📊 Propensity score–matched 1:1
💊 Outcome: chronic opioid use ≥90 days
1️⃣ Background
Opioid use remains high in axSpA — even with effective biologics like TNFi.
We asked: could starting TNFi early lower the risk of chronic opioid use?
Opioid use remains high in axSpA — even with effective biologics like TNFi.
We asked: could starting TNFi early lower the risk of chronic opioid use?
October 14, 2025 at 3:15 PM
1️⃣ Background
Opioid use remains high in axSpA — even with effective biologics like TNFi.
We asked: could starting TNFi early lower the risk of chronic opioid use?
Opioid use remains high in axSpA — even with effective biologics like TNFi.
We asked: could starting TNFi early lower the risk of chronic opioid use?
🧵 New study alert!
💊 Does early TNF inhibitor (TNFi) therapy reduce chronic opioid use in axial spondyloarthritis (axSpA)?
👉 We looked at real-world US data to find out.
📄 Arthritis Care & Research, 2025
🔗 acrjournals.onlinelibrary.wiley.com/doi/10.1002/...
@rheumcat.bsky.social
💊 Does early TNF inhibitor (TNFi) therapy reduce chronic opioid use in axial spondyloarthritis (axSpA)?
👉 We looked at real-world US data to find out.
📄 Arthritis Care & Research, 2025
🔗 acrjournals.onlinelibrary.wiley.com/doi/10.1002/...
@rheumcat.bsky.social
October 14, 2025 at 3:15 PM
🧵 New study alert!
💊 Does early TNF inhibitor (TNFi) therapy reduce chronic opioid use in axial spondyloarthritis (axSpA)?
👉 We looked at real-world US data to find out.
📄 Arthritis Care & Research, 2025
🔗 acrjournals.onlinelibrary.wiley.com/doi/10.1002/...
@rheumcat.bsky.social
💊 Does early TNF inhibitor (TNFi) therapy reduce chronic opioid use in axial spondyloarthritis (axSpA)?
👉 We looked at real-world US data to find out.
📄 Arthritis Care & Research, 2025
🔗 acrjournals.onlinelibrary.wiley.com/doi/10.1002/...
@rheumcat.bsky.social
Reposted by Jose Meade
November 18, 2024 at 2:27 AM
Reposted by Jose Meade
Thanks for the head's up @restovall.bsky.social!
Our mentee Jose Meade-Aguilar's work is cited from #ACR24 here: www.the-rheumatologist.org/article/key-...
Our mentee Jose Meade-Aguilar's work is cited from #ACR24 here: www.the-rheumatologist.org/article/key-...
Key Research in Axial Spondyloarthritis Encapsulated - The Rheumatologist
Our understanding of (axSpA) has really changed, especially with regard to male-female differences. In this report, we identify important research on axSpA presented at ACR Convergence 2024, summarize...
www.the-rheumatologist.org
December 10, 2024 at 9:19 PM
Thanks for the head's up @restovall.bsky.social!
Our mentee Jose Meade-Aguilar's work is cited from #ACR24 here: www.the-rheumatologist.org/article/key-...
Our mentee Jose Meade-Aguilar's work is cited from #ACR24 here: www.the-rheumatologist.org/article/key-...
Reposted by Jose Meade
NEW EPISODE! Alain Sanchez-Rodriguez, MD, joins the podcast to discuss delays in #lupus diagnosis & care based on findings from the Lupus Midwest Network (LUMEN)
🎙️Listen → https://acr.tw/3UWKCXi
#Medsky
🎙️Listen → https://acr.tw/3UWKCXi
#Medsky
September 6, 2025 at 8:40 PM
NEW EPISODE! Alain Sanchez-Rodriguez, MD, joins the podcast to discuss delays in #lupus diagnosis & care based on findings from the Lupus Midwest Network (LUMEN)
🎙️Listen → https://acr.tw/3UWKCXi
#Medsky
🎙️Listen → https://acr.tw/3UWKCXi
#Medsky
Wait you also moved! @rheumcat.bsky.social
September 25, 2025 at 7:54 PM
Wait you also moved! @rheumcat.bsky.social
We had so much fun sharing some Lung POCUS basics to our MS2s @bumedicine.bsky.social! Their names is Ultrasound Is for Everyone and I just love it.
September 25, 2025 at 7:53 PM
We had so much fun sharing some Lung POCUS basics to our MS2s @bumedicine.bsky.social! Their names is Ultrasound Is for Everyone and I just love it.
Thank you @rheumcat.bsky.social for many hours of outstanding mentoring and hard work! What an incredible journey this has been! @rheumresearch.bsky.social
May 15, 2025 at 9:48 PM
Thank you @rheumcat.bsky.social for many hours of outstanding mentoring and hard work! What an incredible journey this has been! @rheumresearch.bsky.social